NasdaqGS:HSIC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Henry Schein, Inc., a solutions company for health care professionals, provides health care products and services to office-based dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. More Details


Snowflake Analysis

Excellent balance sheet and good value.


Similar Companies

Share Price & News

How has Henry Schein's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HSIC has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

2.8%

HSIC

6.3%

US Healthcare

3.9%

US Market


1 Year Return

-4.9%

HSIC

25.6%

US Healthcare

18.5%

US Market

Return vs Industry: HSIC underperformed the US Healthcare industry which returned 22.3% over the past year.

Return vs Market: HSIC underperformed the US Market which returned 17.2% over the past year.


Shareholder returns

HSICIndustryMarket
7 Day2.8%6.3%3.9%
30 Day-11.5%-0.7%-4.3%
90 Day-0.5%0.9%8.1%
1 Year-4.9%-4.9%27.3%25.6%21.2%18.5%
3 Year-8.3%-28.1%26.5%21.0%38.2%29.0%
5 Year8.1%-15.2%55.8%44.6%84.3%63.4%

Price Volatility Vs. Market

How volatile is Henry Schein's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Henry Schein undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: HSIC ($58.78) is trading below our estimate of fair value ($130.07)

Significantly Below Fair Value: HSIC is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: HSIC is good value based on its PE Ratio (14.5x) compared to the US Healthcare industry average (22.3x).

PE vs Market: HSIC is good value based on its PE Ratio (14.5x) compared to the US market (17.9x).


Price to Earnings Growth Ratio

PEG Ratio: HSIC is poor value based on its PEG Ratio (1.1x)


Price to Book Ratio

PB vs Industry: HSIC's PB Ratio (2.8x) is in line with the US Healthcare industry average.


Next Steps

Future Growth

How is Henry Schein forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

13.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HSIC's forecast earnings growth (13.3% per year) is above the savings rate (2.2%).

Earnings vs Market: HSIC's earnings (13.3% per year) are forecast to grow slower than the US market (22.1% per year).

High Growth Earnings: HSIC's earnings are forecast to grow, but not significantly.

Revenue vs Market: HSIC's revenue (6.6% per year) is forecast to grow slower than the US market (9.9% per year).

High Growth Revenue: HSIC's revenue (6.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HSIC's Return on Equity is forecast to be low in 3 years time (13.4%).


Next Steps

Past Performance

How has Henry Schein performed over the past 5 years?

3.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HSIC has a large one-off gain of $167.9M impacting its June 27 2020 financial results.

Growing Profit Margin: HSIC's current net profit margins (6.3%) are higher than last year (4.6%).


Past Earnings Growth Analysis

Earnings Trend: HSIC's earnings have grown by 3.8% per year over the past 5 years.

Accelerating Growth: HSIC's earnings growth over the past year (31.8%) exceeds its 5-year average (3.8% per year).

Earnings vs Industry: HSIC earnings growth over the past year (31.8%) exceeded the Healthcare industry 31.1%.


Return on Equity

High ROE: HSIC's Return on Equity (15.4%) is considered low.


Next Steps

Financial Health

How is Henry Schein's financial position?


Financial Position Analysis

Short Term Liabilities: HSIC's short term assets ($3.4B) exceed its short term liabilities ($2.3B).

Long Term Liabilities: HSIC's short term assets ($3.4B) exceed its long term liabilities ($1.1B).


Debt to Equity History and Analysis

Debt Level: HSIC's debt to equity ratio (28.8%) is considered satisfactory.

Reducing Debt: HSIC's debt to equity ratio has increased from 21.5% to 28.8% over the past 5 years.

Debt Coverage: HSIC's debt is well covered by operating cash flow (46.7%).

Interest Coverage: HSIC's interest payments on its debt are well covered by EBIT (20.7x coverage).


Balance Sheet


Next Steps

Dividend

What is Henry Schein current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HSIC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HSIC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HSIC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HSIC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HSIC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.6yrs

Average management tenure


CEO

Stanley Bergman (70 yo)

31.67yrs

Tenure

US$14,422,944

Compensation

Mr. Stanley M. Bergman has been the Chief Executive Officer and Executive Chairman of Henry Schein, Inc. since 1989. Mr. Bergman has been an Executive Director of Henry Schein, Inc. since 1982. He served a ...


CEO Compensation Analysis

Compensation vs Market: Stanley's total compensation ($USD14.42M) is above average for companies of similar size in the US market ($USD7.33M).

Compensation vs Earnings: Stanley's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Stanley Bergman
Executive Chairman & CEO31.67yrsUS$14.42m0.59%
$ 49.3m
James Breslawski
Executive Vice Chairman & President2.33yrsUS$3.23m0.11%
$ 9.2m
Steven Paladino
Executive VP27.75yrsUS$3.38m0.056%
$ 4.7m
Gerald Benjamin
Executive VP26yrsUS$3.32m0.084%
$ 7.0m
Mark Mlotek
Executive VP25yrsUS$3.01m0.030%
$ 2.5m
Ronald South
Chief Accounting Officer & VP of Corporate Financeno datano datano data
Christopher Pendergast
Senior VP & CTO2.42yrsno datano data
Carolynne Borders
Vice President of Investor Relations7.83yrsno datano data
Walter Siegel
Senior VP & General Counsel6.92yrsno data0.036%
$ 3.0m
John Lee
Vice President of Global Compensation & Benefitsno datano datano data
Gerard Meuchner
Chief Global Communications Officer & VP8.5yrsno datano data
Lorelei McGlynn
Senior VP & Chief Human Resources Officer7.33yrsno datano data

8.6yrs

Average Tenure

63yo

Average Age

Experienced Management: HSIC's management team is seasoned and experienced (8.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Stanley Bergman
Executive Chairman & CEO31.67yrsUS$14.42m0.59%
$ 49.3m
James Breslawski
Executive Vice Chairman & President2.33yrsUS$3.23m0.11%
$ 9.2m
Steven Paladino
Executive VP27.75yrsUS$3.38m0.056%
$ 4.7m
Gerald Benjamin
Executive VP26yrsUS$3.32m0.084%
$ 7.0m
Mark Mlotek
Executive VP25yrsUS$3.01m0.030%
$ 2.5m
Philip Laskawy
Independent Lead Director8.67yrsUS$337.00kno data
Paul Brons
Independent Director15.42yrsUS$278.20k0.011%
$ 893.7k
Joseph Herring
Independent Director4.33yrsUS$317.40k0.0086%
$ 725.9k
Louis Sullivan
Chairman of Medical Advisory Board14.17yrsUS$280.70kno data
Norman Matthews
Member of Medical Advisory Boardno dataUS$287.96kno data
Barry Alperin
Independent Director24.33yrsUS$318.00k0.032%
$ 2.7m
Kurt Kuehn
Independent Director4.33yrsUS$313.60k0.0030%
$ 254.3k

15.4yrs

Average Tenure

68.5yo

Average Age

Experienced Board: HSIC's board of directors are seasoned and experienced ( 15.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: HSIC insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Henry Schein, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Henry Schein, Inc.
  • Ticker: HSIC
  • Exchange: NasdaqGS
  • Founded: 1932
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: US$8.392b
  • Shares outstanding: 142.77m
  • Website: https://www.henryschein.com

Number of Employees


Location

  • Henry Schein, Inc.
  • 135 Duryea Road
  • Melville
  • New York
  • 11747
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HSICNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 1995
HS2DB (Deutsche Boerse AG)YesCommon StockDEEURNov 1995
0L3CLSE (London Stock Exchange)YesCommon StockGBUSDNov 1995
HSICWBAG (Wiener Boerse AG)YesCommon StockATEURNov 1995
H1SI34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 2 REPR 1 COMBRBRLJan 2020

Biography

Henry Schein, Inc., a solutions company for health care professionals, provides health care products and services to office-based dental practitioners and laboratories, physician practices, government, ins ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/30 23:41
End of Day Share Price2020/09/30 00:00
Earnings2020/06/27
Annual Earnings2019/12/28


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.